|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2006-8-21
|
|
pubmed:abstractText |
To improve survival and reduce toxicity in primary CNS lymphoma (PCNSL) treatment, we conducted a multicenter phase II study with early high-dose chemotherapy (HDT) and autologous stem-cell transplantation (ASCT) followed by hyperfractionated whole-brain radiotherapy (WBRT) for newly diagnosed PCNSL patients younger than 65 years of age.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3865-70
|
|
pubmed:meshHeading |
pubmed-meshheading:16864853-Adult,
pubmed-meshheading:16864853-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16864853-Carmustine,
pubmed-meshheading:16864853-Central Nervous System Neoplasms,
pubmed-meshheading:16864853-Chemotherapy, Adjuvant,
pubmed-meshheading:16864853-Cranial Irradiation,
pubmed-meshheading:16864853-Cytarabine,
pubmed-meshheading:16864853-Dose Fractionation,
pubmed-meshheading:16864853-Drug Administration Schedule,
pubmed-meshheading:16864853-Female,
pubmed-meshheading:16864853-Germany,
pubmed-meshheading:16864853-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16864853-Humans,
pubmed-meshheading:16864853-Lymphoma,
pubmed-meshheading:16864853-Male,
pubmed-meshheading:16864853-Methotrexate,
pubmed-meshheading:16864853-Middle Aged,
pubmed-meshheading:16864853-Radiotherapy, Adjuvant,
pubmed-meshheading:16864853-Thiotepa,
pubmed-meshheading:16864853-Transplantation, Autologous,
pubmed-meshheading:16864853-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
|
|
pubmed:affiliation |
Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany.
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|
